Diasome Pharmaceuticals, Inc is establishing an Insulin Adjustment Committee (IAC) to be virtually staffed by Certified Diabetes Care and Education Specialist (CDCES) in a contractor role. The purpose of the IAC is to evaluate whether MDI Intensive Insulin Therapy dose adjustment by investigators in a Diasome-sponsored Phase 2b clinical trial in T1D is consistent with protocol specifications. The IAC member will review glycemic values and insulin dosing data contained in a case-file for a given visit. An assessment of whether protocol-specified insulin adjustment was performed will be based on pre-specfied criteria.